These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 39250492)

  • 1. Economic evaluation on meningococcal vaccination strategies among children under nine years of age in Zhejiang province, China.
    Shen J; Ji C; Luo X; Hu Y
    PLoS One; 2024; 19(9):e0310274. PubMed ID: 39250492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of vaccination strategies against meningococcal disease for children under nine years of age in China.
    Zhang H; Zhang H; Fang H
    Hum Vaccin Immunother; 2024 Dec; 20(1):2313872. PubMed ID: 38348600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary immunization of meningococcal meningitis vaccine among children in Hangzhou, China, 2008-2017.
    Che X; Liu Y; Wang J; Xu Y; Zhang X; Gu W; Jiang W; Du J; Zhang X
    Hum Vaccin Immunother; 2021 Apr; 17(4):1239-1243. PubMed ID: 32961071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile.
    Villena R; Valenzuela MT; Bastías M; Santolaya ME
    Vaccine; 2019 Oct; 37(46):6915-6921. PubMed ID: 31585728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of expanding childhood routine immunization against Neisseria meningitidis serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt.
    Kuznik A; Iliyasu G; Lamorde M; Mahmud M; Musa BM; Nashabaru I; Obaro S; Mohammed I; Habib AG
    PLoS One; 2017; 12(11):e0188595. PubMed ID: 29190699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.
    Hepkema H; Pouwels KB; van der Ende A; Westra TA; Postma MJ
    PLoS One; 2013; 8(5):e65036. PubMed ID: 23741448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.
    Pouwels KB; Hak E; van der Ende A; Christensen H; van den Dobbelsteen GP; Postma MJ
    Hum Vaccin Immunother; 2013 May; 9(5):1129-38. PubMed ID: 23406816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study.
    Yaesoubi R; Trotter C; Colijn C; Yaesoubi M; Colombini A; Resch S; Kristiansen PA; LaForce FM; Cohen T
    PLoS Med; 2018 Jan; 15(1):e1002495. PubMed ID: 29364884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
    Si S; Zomer E; Fletcher S; Lee J; Liew D
    Vaccine; 2019 Aug; 37(35):5009-5015. PubMed ID: 31301916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine.
    Watle SV; Næss LM; Tunheim G; Caugant DA; Wisløff T
    Hum Vaccin Immunother; 2021 Aug; 17(8):2777-2787. PubMed ID: 33631080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
    Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
    Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model.
    Régnier SA; Huels J
    Hum Vaccin Immunother; 2014; 10(12):3737-45. PubMed ID: 25483706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction.
    Villena R; Valenzuela MT; Bastías M; Santolaya ME
    Vaccine; 2022 Jan; 40(4):666-672. PubMed ID: 34996641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
    J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
    Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
    Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.